ESMO 23: Pluvicto Fulfils Promise For Prostate Cancer Label Expansion

 
• By Kevin Grogan

Novartis' radioligand therapy has performed well against standard-of-care androgen-receptor pathway inhibitor therapy and could potentially be a paradigm shift in the treatment of prostate cancer.

Novartis HQ
• Source: Novartis

More from Anticancer

More from Therapy Areas